Tirzepatide, a once-weekly GIP/GLP-1 receptor agonist, is a medicine used for weight reduction in adults with obesity. A new analysis of the SURMOUNT clinical trials reveals that the medicine, ...
Share on Pinterest Mounjaro helps maintain weight loss at 3-year landmark, study confirms. Image credit: NurPhoto/Getty Images. According to a new study, a once-weekly dose of tirzepatide can lead to ...
Please provide your email address to receive an email when new articles are posted on . Of adults who did not lose 5% of their weight with tirzepatide at 12 weeks, 90% achieved 5% weight loss at 72 ...
In the context of the global obesity epidemic, the FDA approved several glucagon-like peptide-1 (GLP-1) receptor agonists (GPL-1RAs), such as liraglutide (Saxenda) and semaglutide (Ozempic, Wegovy) as ...
A new once-a-month injection helped people with obesity shed up to 16% of their body weight, offering fresh hope for effective, long-acting treatments. Can this breakthrough change the landscape for ...
Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed mean weight reduction in the highest range of efficacy observed with existing weight loss ...
Study reveals that GLP-1 therapy increases visceral adipose tissue metabolism, significantly contributing to weight loss in individuals with obstructive sleep apnea. Study: GLP-1 therapy increases ...
Evidence from multiple trials shows semaglutide, known for weight loss and diabetes control, also reduces chronic inflammation through mechanisms not solely tied to fat loss. This anti-inflammatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results